

Appendix Table F65. Clinical outcomes after botulinum toxin vs. placebo, individual RCTs

Reference sample	Dose	Outcome	Active n/N	Control n/N	Relative risk	Lower 95% CI	Upper 95% CI	Absolute risk difference	Lower 95% CI	Upper 95% CI	Number needed to treat	Attributable events/1000 treated
Brubaker, 2008 ²³⁸ 84	200U-single dose	>75% decreased number of incontinence episodes	18/28	0/15	20.41	1.32	316.75	0.643	0.448	0.837	2	643
Brubaker, 2008 ²³⁸ 84	200U-single dose	Serious adverse events	3/28	2/15	0.80	0.15	4.29	-0.026	-0.233	0.180		
Brubaker, 2008 ²³⁸ 84	200U-single dose	Unexpected adverse events	6/28	0/15	7.17	0.43	119.24	0.214	0.040	0.388	5	214
Brubaker, 2008 ²³⁸ 84	200U-single dose	Treatment failure	6/28	11/15	0.29	0.14	0.63	-0.519	-0.790	-0.249	-2	-519
Brubaker, 2008 ²³⁸ 84	200U-single dose	Urinary tract infection	12/28	3/15	2.14	0.71	6.43	0.229	-0.045	0.502		
Brubaker, 2008 ²³⁸ 84	200U-single dose	Increase in post-void residual volume	12/28	0/15	13.79	0.87	217.93	0.429	0.229	0.628	2	429
Brubaker, 2008 ²³⁸ 84	200U-single dose	Urinary tract infection without increased PVR	3/28	3/15	0.54	0.12	2.34	-0.093	-0.325	0.140		